Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

The DRDC have the first set of animals (soman controls and bucillamine pretreated) completed and is now performing the assays looking at GABA receptor downregulation. Over the next few weeks data will be collected and analysed for effect size. Should the data show significant effects, Revive and the DRDC will discuss on the future development path. The results from this research study, if promising, will determine further studies to facilitate FDA and Health Canada approvals for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning and explore its potential for traumatic brain injury caused by concussive or explosive forces and viral infections. Read More

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure